SEARCH:   Advanced

Prepublished online as a Blood First Edition Paper on May 1, 2003; DOI 10.1182/blood-2003-03-0744. This Article Full Text (PDF) All Versions of this Article: 2003-03-0744v1 102/5/1869    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Kralovics, R. Articles by Skoda, R. C Search for Related Content PubMed PubMed Citation Articles by Kralovics, R. Articles by Skoda, R. C Social Bookmarking                   What's this? Submitted March 10, 2003 Accepted April 21, 2003 Comparison of molecular markers in a cohort of patients with chronic myeloproliferative disorders Robert Kralovics, Andreas S Buser, Soon-Siong Teo, Joern Coers, Andre Tichelli, Anthonie P C van der Maas, and Radek C Skoda* Department of Research, Division of Experimental Hematology, Basel University Hospital, Basel, Switzerland Department of Medicine, Division of Hematology, Basel University Hospital, Basel, Switzerland Department of Laboratory Medicine, Division of Diagnostic Hematology, Basel University Hospital, Basel, Switzerland Department of Internal Medicine, Medical Centre Haaglanden, The Hague, The Netherlands * Corresponding author; email: radek.skoda{at}unibas.ch. Decreased expression of c-MPL protein in platelets, increased expression of PRV-1 and NFIB mRNA in granulocytes and loss of heterozygosity on chromosome 9p (9pLOH) were described as molecular markers for myeloproliferative disorders (MPD). To assess whether these markers are clustered in subgroups of MPD or represent independent phenotypic variations, we simultaneously determined their status in a cohort of MPD patients. Growth of erythropoietin-independent colonies (EEC) was measured for comparison. We observed concordance between EEC and PRV-1 in MPD patients across all diagnostic subclasses, but our results indicate that EEC remain the most reliable auxiliary test for polycythemia vera (PV). In contrast, c-MPL, NFIB and 9pLOH constitute independent variations. Interestingly, decreased c-MPL and elevated PRV-1 were also observed in patients with hereditary thrombocythemia (HT) who carry a mutation in the thrombopoietin (TPO) gene. Thus, altered c-MPL and PRV-1 expression can also arise through a molecular mechanism different from sporadic MPD. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: F. X. Schaub, R. Jager, R. Looser, H. Hao-Shen, S. Hermouet, F. Girodon, A. Tichelli, H. Gisslinger, R. Kralovics, and R. C. Skoda Clonal analysis of deletions on chromosome 20q and JAK2-V617F in MPD suggests that del20q acts independently and is not one of the predisposing mutations for JAK2-V617F Blood, February 26, 2009; 113(9): 2022 - 2027. [Abstract] [Full Text] [PDF] R. Tiedt, J. Coers, S. Ziegler, A. Wiestner, H. Hao-Shen, C. Bornmann, J. Schenkel, S. Karakhanova, F. J. de Sauvage, C. W. Jackson, et al. Pronounced thrombocytosis in transgenic mice expressing reduced levels of Mpl in platelets and terminally differentiated megakaryocytes Blood, February 19, 2009; 113(8): 1768 - 1777. [Abstract] [Full Text] [PDF] K. Liu, R. Kralovics, Z. Rudzki, B. Grabowska, A. S. Buser, D. Olcaydu, H. Gisslinger, R. Tiedt, P. Frank, K. Okon, et al. A de novo splice donor mutation in the thrombopoietin gene causes hereditary thrombocythemia in a Polish family Haematologica, May 1, 2008; 93(5): 706 - 714. [Abstract] [Full Text] [PDF] R. Tiedt, H. Hao-Shen, M. A. Sobas, R. Looser, S. Dirnhofer, J. Schwaller, and R. C. Skoda Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice Blood, April 15, 2008; 111(8): 3931 - 3940. [Abstract] [Full Text] [PDF] S. Li, R. Kralovics, G. De Libero, A. Theocharides, H. Gisslinger, and R. C. Skoda Clonal heterogeneity in polycythemia vera patients with JAK2 exon12 and JAK2-V617F mutations Blood, April 1, 2008; 111(7): 3863 - 3866. [Abstract] [Full Text] [PDF] S. Bauer, M. Abdgawad, L. Gunnarsson, M. Segelmark, H. Tapper, and T. Hellmark Proteinase 3 and CD177 are expressed on the plasma membrane of the same subset of neutrophils J. Leukoc. Biol., February 1, 2007; 81(2): 458 - 464. [Abstract] [Full Text] [PDF] R. Skoda The Genetic Basis of Myeloproliferative Disorders Hematology, January 1, 2007; 2007(1): 1 - 10. [Abstract] [Full Text] [PDF] D. P. Steensma JAK2 V617F in Myeloid Disorders: Molecular Diagnostic Techniques and Their Clinical Utility: A Paper from the 2005 William Beaumont Hospital Symposium on Molecular Pathology J. Mol. Diagn., September 1, 2006; 8(4): 397 - 411. [Abstract] [Full Text] [PDF] R. Kralovics, S.-S. Teo, S. Li, A. Theocharides, A. S. Buser, A. Tichelli, and R. C. Skoda Acquisition of the V617F mutation of JAK2 is a late genetic event in a subset of patients with myeloproliferative disorders Blood, August 15, 2006; 108(4): 1377 - 1380. [Abstract] [Full Text] [PDF] O. Bock, G. Busche, C. Koop, S. Schroter, T. Buhr, and H. Kreipe Detection of the Single Hotspot Mutation in the JH2 Pseudokinase Domain of Janus Kinase 2 in Bone Marrow Trephine Biopsies Derived from Chronic Myeloproliferative Disorders J. Mol. Diagn., May 1, 2006; 8(2): 170 - 177. [Abstract] [Full Text] [PDF] R. Kralovics, S.-S. Teo, A. S. Buser, M. Brutsche, R. Tiedt, A. Tichelli, F. Passamonti, D. Pietra, M. Cazzola, and R. C. Skoda Altered gene expression in myeloproliferative disorders correlates with activation of signaling by the V617F mutation of Jak2 Blood, November 15, 2005; 106(10): 3374 - 3376. [Abstract] [Full Text] [PDF] P. S. Goerttler, C. Steimle, E. Marz, P. L. Johansson, B. Andreasson, M. Griesshammer, H. Gisslinger, H. Heimpel, and H. L. Pahl The Jak2V617F mutation, PRV-1 overexpression, and EEC formation define a similar cohort of MPD patients Blood, October 15, 2005; 106(8): 2862 - 2864. [Abstract] [Full Text] [PDF] A. V. Jones, S. Kreil, K. Zoi, K. Waghorn, C. Curtis, L. Zhang, J. Score, R. Seear, A. J. Chase, F. H. Grand, et al. Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders Blood, September 15, 2005; 106(6): 2162 - 2168. [Abstract] [Full Text] [PDF] A. Tefferi and D. G. Gilliland The JAK2V617F Tyrosine Kinase Mutation in Myeloproliferative Disorders: Status Report and Immediate Implications for Disease Classification and Diagnosis Mayo Clin. Proc., July 1, 2005; 80(7): 947 - 958. [Abstract] [PDF] R. Kralovics, F. Passamonti, A. S. Buser, S.-S. Teo, R. Tiedt, J. R. Passweg, A. Tichelli, M. Cazzola, and R. C. Skoda A Gain-of-Function Mutation of JAK2 in Myeloproliferative Disorders N. Engl. J. Med., April 28, 2005; 352(17): 1779 - 1790. [Abstract] [Full Text] [PDF] P. J. Campbell and A. R. Green Management of Polycythemia Vera and Essential Thrombocythemia Hematology, January 1, 2005; 2005(1): 201 - 208. [Abstract] [Full Text] [PDF] L. Teofili, M. Martini, F. Guidi, D. Venditti, G. Leone, and M. L. Larocca The PRV-1 gene expression in essential thrombocythemia Blood, November 1, 2004; 104(9): 2995 - 2996. [Full Text] [PDF] J. Coers, C. Ranft, and R. C. Skoda A Truncated Isoform of c-Mpl with an Essential C-terminal Peptide Targets the Full-length Receptor for Degradation J. Biol. Chem., August 27, 2004; 279(35): 36397 - 36404. [Abstract] [Full Text] [PDF] T. Schomber, C. P. Kalberer, A. Wodnar-Filipowicz, and R. C. Skoda Gene silencing by lentivirus-mediated delivery of siRNA in human CD34+ cells Blood, June 15, 2004; 103(12): 4511 - 4513. [Abstract] [Full Text] [PDF] A. Tefferi, T. L. Lasho, A. P. Wolanskyj, and R. A. Mesa Neutrophil PRV-1 expression across the chronic myeloproliferative disorders and in secondary or spurious polycythemia Blood, May 1, 2004; 103(9): 3547 - 3548. [Abstract] [Full Text] [PDF] L. Florensa, C. Besses, L. Zamora, B. Bellosillo, B. Espinet, S. Serrano, S. Woessner, and F. Sole Endogenous erythroid and megakaryocytic circulating progenitors, HUMARA clonality assay, and PRV-1 expression are useful tools for diagnosis of polycythemia vera and essential thrombocythemia Blood, March 15, 2004; 103(6): 2427 - 2428. [Full Text] [PDF] D. Cilloni, S. Carturan, E. Gottardi, F. Messa, M. Fava, I. Defilippi, F. Arruga, G. Saglio, S. Klippel, P. S. Goerttler, et al. Usefulness of the quantitative assessment of PRV-1 gene expression for the diagnosis of polycythemia vera and essential thrombocythemia patients Blood, March 15, 2004; 103(6): 2428 - 2429. [Full Text] [PDF] L. Palmqvist, P. Goerttler, C. Wasslavik, P. Johansson, B. Andreasson, S. Safai-Kutti, J. Kutti, H. L. Pahl, and A. Ricksten Comparison of Methods for Polycythemia Rubra Vera-1 mRNA Quantification in Whole-Blood Leukocytes and Purified Granulocytes Clin. Chem., March 1, 2004; 50(3): 644 - 647. [Full Text] [PDF] J. F. Prchal and J. T. Prchal A specific test for polycythemia vera? Blood, November 15, 2003; 102(10): 3464 - 3464. [Full Text] [PDF]

	Copyright © 2003 by American Society of Hematology         Online ISSN: 1528-0020